How to calculate the quantity of CD34+ cells infused? A single center cohort study based on actual, ideal or adjusted ideal body weight

Transfusion and Apheresis Science

Volumn 36, Issue 3, 2007, Pages 275-280

  Topcuoglu, Pervin ^a   Akcaglayan Soydan, Ender ^a   Ekiz, Fuat ^a   Ayyildiz, Erol ^a   Dalva, Klara ^a   Ozcan, Muhit ^a   Arslan, Onder ^a   Arat, Mutlu ^a   Ilhan, Osman ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

CD34+ cells; Ideal body weight; Neutrophil engraftment; Stem cell collection

Indexed keywords

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BODY WEIGHT; COHORT ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTIGENS, CD34; BODY WEIGHT; CELL COUNT; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 34447618588     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2007.03.007     Document Type: Article

References (19)

1. Weaver C.H., Hazelton B., Birch R., Palmer P., Allen C., Schwartzberg L., et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after administration of myeloablative chemotherapy. Blood 86 (1996) 3961-3969
2. Mavroudis D., Read E., Cottler-Fox M., Couriel D., Molldrem J., Carter C., et al. CD34+ cell dose predicts survival, post transplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 88 (1996) 3223-3229
3. Ilhan O., Arslan O., Arat M., Beksac M., Akan H., Ozcan M., et al. The impact of CD34 cell dose on the engraftment in allogeneic peripheral blood stem cell transplantation. Transfus. Sci. 10 (1999) 69-71
4. Zimmerman T.M., Lee W.J., Bender J.G., Mick R., and Williams S.F. Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transpl. 9 (1995) 439-444
5. Waples J.M., Moreb J.S., Sugrue M., Belanger G., Kubilis P., Lynch J.W., et al. Comparison of autologous peripheral blood stem cell dosing by ideal vs. actual body weight. Bone Marrow Transpl. 23 (1999) 867-873
6. Ali M.Y., Oyama Y., Monreal J., Winter J.N., Tallman M.S., Williams S.F., et al. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?. Bone Marrow Transpl. 31 (2003) 861-864
7. Cilley J., Rihn C., Monreal J., Gordon L.I., Singhal S., Tallman M., et al. Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?. Bone Marrow Transpl. 33 (2004) 161-164
8. Singhal S., Gordon L.I., Tallman M.S., Winter J.N., Evens A.O., Frankfurt O., et al. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 37 (2006) 553-557
9. Dickson T.M., Kusnierz-Glaz C.R., Blume K.G., Negrin R.S., Hu W.W., Shizuru J.A., et al. Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biol. Blood Bone Marrow Transpl. 5 (1999) 299-305
10. Gren B., and Duffull S.B. What is the best size descriptor to use for pharmacocinetic studies in the obese. Br. J. Clin. Pharmacol. 58 (2004) 119-133
11. Ustun C., Arslan O., Beksac M., Koc H., Gurman G., Ozcelik T., et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Biol. Blood Marrow Transpl. 5 (1999) 28-35
12. Gurman G., Dilek I., Arslan O., Arat M., Beksac M., Ilhan O., et al. The effect of G-CSF on lymphocyte subsets and CD34+ cells in allogeneic stem cell transplantation. Transfus. Apher. Sci. 24 (2001) 23-28
13. Arat M., Arslan O., Ayyildiz E., Topcuoglu P., Dalva K., and Ilhan O. Peripheral blood stem cell apheresis for allogeneic transplants: Ibni Sina experience. Transfus. Apher. Sci. 30 (2004) 189-191
14. Devine D.J. Gentamycin therapy. Drug Intell. Clin. Pharm. 4 (1974) 650-655
15. Ireton-Jones C.S., and Turner Jr. W.W. Actual or ideal body weight: which should be used to predict energy expenditure?. J. Am. Diet. Assoc. 91 (1991) 193-195
16. Sutherland D.R., Anderson L., Keeney M., Nayar R., and Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J. Hematother. 5 (1996) 213-226
17. Perez-Simon J.A., Martin A., Caballero D., Corral M., Nieto M.J., Gonzalez M., et al. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transpl. 24 (1999) 1279-1283
18. Scheid C., Draube A., Reiser M., Schulz A., Chemnitz J., Nelles S., et al. Using at least 5 × 10(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transpl. 23 (1999) 1177-1181
19. Gandhi M.K., Jestice K., Scott M.A., Bloxham D., Bass G., and Marcus R.E. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transpl. 23 (1999) 9-13